Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rio Tinto CEO exit a 'big surprise', says Berenberg

(Sharecast News) - Berenberg has kept a 'buy' rating on Rio Tinto but said that Thursday's news of its chief executive's resignation came as a "big surprise". The mining group unexpectedly announced that boss Jakob Stausholm will leave the company later this year after four years in the role, calling it a "natural moment" for a change in leadership

"This news comes as a big surprise and in our view was not expected; no clear reason for his departure has been given by the company other than to state that now is 'a natural moment' to appoint a successor - but it does not feel that natural to us," Berenberg said in a research note.

The broker credited Stausholm as leading a "major cultural rebrand" at Rio, including the company's shift to lithium - the firm just this year completed the $6.7bn acquisition of Arcadium Lithium - as he aligned the miner with the energy transition.

"We had expected Mr Stausholm to remain with the company and drive the integration of the lithium business, so his exit comes as a surprise, given the recent acquisition and strategic step," Berenberg said.

On possible successors for Stausholm's position, the broker highlighted chief commercial officer Bold Baatar and the head of the iron ore division Simon Trott as potential candidates, along with the head of Australian operations Kellie Parker, CFO Peter Cunningham and minerals lead Sinead Kaufman.

Nevertheless, with a 6,200p target price for the stock indicating 33% upside from Wednesday's close, Berenberg stuck with a positive view of the shares.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.